Stocks TelegraphStocks Telegraph
Stock Ideas

PTCT Financial Statements and Analysis

NASDAQ : PTCT

PTC Therapeutics

$78.74
0.1732+0.22%
Open: 2:57 PM
69.77
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
revenue211.007M178.875M1.176B196.786M186.704M
cost of revenue115.939M11.42M12.862M10.848M18.392M
gross profit95.068M167.455M1.163B185.938M168.312M
gross profit ratio0.4510.9360.9890.9450.901
research and development expenses100.158M112.99M108.973M161.412M132.169M
general and administrative expenses00000
selling and marketing expenses00000
selling general and administrative expenses84.046M85.262M80.961M73.456M69.50M
other expenses-92.152M4.16M3.075M5.58M-2.025M
operating expenses92.052M202.412M193.009M240.448M201.669M
cost and expenses207.991M213.832M205.871M251.296M220.061M
interest income00000
interest expense32.592M30.358M34.092M41.609M43.49M
depreciation and amortization11.109M7.583M7.221M6.486M7.018M
ebitda20.627M-33.111M971.141M-49.896M-35.225M
ebitda ratio0.098-0.1850.826-0.254-0.141
operating income3.016M-34.957M970.225M-54.51M-33.357M
operating income ratio0.014-0.1950.825-0.277-0.179
total other income expenses net-26.09M-36.095M-40.397M-43.481M-45.515M
income before tax-23.074M-71.052M929.828M-97.991M-85.733M
income before tax ratio-0.109-0.3970.791-0.498-0.459
income tax expense-38.97M-6.203M63.266M8.663M13.446M
net income15.896M-64.849M866.562M-106.654M-99.179M
net income ratio0.075-0.3630.737-0.542-0.531
eps0.20-0.8311.09-1.39-1.29
eps diluted0.20-0.8310.04-1.39-1.29
weighted average shs out81.497M78.151M78.116M76.926M76.725M
weighted average shs out dil87.115M78.151M86.386M76.926M76.725M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
cash and cash equivalents672.617M1.017B1.48B526.001M654.779M
short term investments1.035B971.764M546.95M487.356M438.514M
cash and short term investments1.707B1.989B2.027B1.013B1.093B
net receivables203.074M196.133M210.495M199.976M187.15M
inventory52.688M34.061M21.675M35.671M31.826M
other current assets44.731M53.531M57.055M32.546M45.641M
total current assets2.008B2.273B2.316B1.282B1.358B
property plant equipment net137.652M113.351M116.776M122.64M123.122M
goodwill82.341M82.341M82.341M82.341M82.341M
intangible assets396.466M143.806M118.448M330.368M329.879M
goodwill and intangible assets478.807M226.147M200.789M412.709M412.22M
long term investments000013.763M
tax assets0000-1.00
other non current assets19.438M21.782M21.416M25.337M9.34M
total non current assets635.897M361.28M338.981M560.686M558.445M
other assets00001.00
total assets2.644B2.634B2.655B1.842B1.916B
account payables36.617M26.505M15.15M13.292M24.279M
short term debt561.413M17.083M16.511M16.755M32.012M
tax payables039.923M64.622M6.012M3.699M
deferred revenue09.76M12.833M03.699M
other current liabilities268.215M534.538M486.275M574.653M549.813M
total current liabilities866.245M627.809M595.391M610.712M609.803M
long term debt1.931B371.083M373.104M383.45M379.498M
deferred revenue non current000079.118M
deferred tax liabilities non current00055.909M55.911M
other non current liabilities2.579M1.842B1.873B1.847B1.851B
total non current liabilities1.933B2.213B2.246B2.286B2.287B
other liabilities00000
capital lease obligations123.807M102.153M103.903M115.099M94.692M
total liabilities2.799B2.841B2.841B2.897B2.897B
preferred stock00000
common stock79.00K78.00K78.00K76.00K76.00K
retained earnings-2.829B-2.845B-2.78B-3.581B-3.474B
accumulated other comprehensive income loss5.93M7.356M-13.949M-4.343M-16.498M
other total stockholders equity2.667B2.631B2.608B2.531B2.511B
total stockholders equity-155.758M-206.546M-185.76M-1.054B-980.181M
total equity-155.758M-206.546M-185.76M-1.054B-980.181M
total liabilities and stockholders equity2.644B2.634B2.655B1.842B1.916B
minority interest00000
total investments1.035B971.764M546.95M487.356M452.277M
total debt2.492B388.166M389.615M400.205M395.504M
net debt1.819B-629.22M-1.091B-125.796M-259.275M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202520242024
periodQ3Q2Q1Q3Q2
deferred income tax-4.00K-2.00K2.00K-3.00K2.00K
stock based compensation19.426M18.543M18.06M19.755M19.243M
change in working capital-84.876M-16.72M-37.397M-54.332M-11.178M
accounts receivables-6.474M21.901M-47.792M-7.719M8.19M
inventory-18.526M-10.782M2.191M-3.106M-1.936M
accounts payables0004.972M0
other working capital-59.876M-27.839M8.204M-87.458M-17.432M
other non cash items-27.852M-2.888M15.655M57.756M39.666M
net cash provided by operating activities-66.301M-58.333M870.103M-76.992M-71.453M
investments in property plant and equipment-3.445M-1.317M-1.724M54.241M7.375M
acquisitions net000-28.038M28.038M
purchases of investments-233.611M-536.649M-327.544M-219.077M-195.702M
sales maturities of investments200.183M118.634M145.646M175.237M94.366M
other investing activites-252.75M-2.677M-738.00K-25.038M28.038M
net cash used for investing activites-289.623M-422.009M-184.36M-42.675M-65.923M
debt repayment000-7.02M0
common stock issued0015.751M-6.72M4.69M
common stock repurchased00000
dividends paid00000
other financing activites15.219M3.961M-6.341M-3.887M241.792M
net cash used provided by financing activities15.219M3.961M9.41M-17.627M246.482M
effect of forex changes on cash-4.064M13.588M5.393M8.542M-5.187M
net change in cash-344.769M-462.793M700.546M-114.989M106.424M
cash at end of period672.617M1.033B1.496B539.79M654.779M
cash at beginning of period1.017B1.496B795.316M654.779M548.355M
operating cashflow-66.301M-58.333M870.103M-76.992M-71.453M
capital expenditure-3.445M-3.994M-2.532M54.241M7.375M
free cash flow-69.746M-62.327M867.571M-22.751M-64.078M
Graph

Frequently Asked Questions

How did PTC Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, PTCT generated $211.01M in revenue last quarter, while its costs came in at $115.94M.
Last quarter, how much Gross Profit did PTC Therapeutics, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. PTC Therapeutics, Inc. reported a $95.07M Gross Profit for the quarter ended Sep 30, 2025.
Have PTCT's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. PTCT incurred $92.05M worth of Operating Expenses, while it generated $3.02M worth of Operating Income.
How much Net Income has PTCT posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from PTC Therapeutics, Inc., the company generated $15.90M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did PTC Therapeutics, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to PTC Therapeutics, Inc. as of the end of the last quarter was $672.62M.
What are PTCT's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, PTCT had Total Net Receivables of $203.07M.
In terms of Total Assets and Current Assets, where did PTC Therapeutics, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of PTCT were $2.01B, while the Total Assets stand at $2.64B.
As of the last quarter, how much Total Debt did PTC Therapeutics, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of PTCT's debt was $2.49B at the end of the last quarter.
What were PTCT's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, PTCT reported total liabilities of $2.80B.
How much did PTCT's Working Capital change over the last quarter?
Working Capital Change for PTCT was -$84.88M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
PTCT generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. PTCT generated -$66.30M of Cash from Operating Activities during its recently reported quarter.
What was PTCT's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. PTCT reported a -$344.77M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph